Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,046 Cr
Revenue (TTM)
₹129 Cr
Net Profit (TTM)
₹57 Cr
ROE
19.4 %
ROCE
26 %
P/E Ratio
18.2
P/B Ratio
3.3
Industry P/E
26.24
EV/EBITDA
12.7
Div. Yield
0.3 %
Debt to Equity
0
Book Value
₹373.6
EPS
₹66.9
Face value
10
Shares outstanding
8,582,670
CFO
₹239.60 Cr
EBITDA
₹325.32 Cr
Net Profit
₹269.62 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
3B Blackbio Dx
| -15.4 | -18.5 | -14.7 | -28.6 | 43.1 | 32.3 | 62.7 |
|
BSE Commodities
| -5.7 | -10.4 | -5.2 | 4.2 | 15.4 | 12.4 | 15.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
3B Blackbio Dx
| -27.5 | 144.7 | 69.5 | 4.4 | 25.2 | 292.9 | -0.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Commodities
| 12.5 | 8.1 | 17.5 | 1.2 | 61.5 | 26.1 | -4.6 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
3B Blackbio Dx
|
1,189.0 | 1,046.0 | 129.0 | 58.2 | 42.4 | 20.3 | 18.2 | 3.3 |
| 4,418.9 | 20,235.2 | 5,620.6 | 670.4 | 13.4 | 22.4 | 30.2 | 6.3 | |
| 175.5 | 2,363.2 | 500.5 | 13.2 | 5.5 | 1.9 | 178.8 | 3.4 | |
| 1,263.0 | 2,221.9 | 1,240.4 | 132.3 | 13.1 | 12.2 | 16.7 | 1.8 | |
| 955.5 | 4,292.4 | 1,978.5 | 265.0 | 16.3 | 18 | 16.2 | 2.7 | |
| 554.0 | 1,669.9 | 2,072.7 | 140.8 | 9.5 | 12.4 | 11.8 | 1.4 | |
| 136.7 | 3,141.5 | 1,424.9 | -44.7 | -1.1 | -13.7 | -- | 4.6 | |
| 227.3 | 4,593.4 | 2,871.0 | 167.0 | 7.8 | 11.7 | 27.5 | 2.2 | |
| 914.8 | 8,562.8 | 5,031.2 | 565.9 | 9.9 | 21.9 | 15.1 | 3.0 | |
| 374.4 | 19,307.0 | 3,234.0 | 531.4 | 18.3 | 17.8 | 36.3 | 5.9 |
No Review & Analysis are available.
Kilpest India Limited, an agriculture based company, manufactures and sells pesticides and other agrochemical products in India. Its chemical products include insecticides, anti-bacterial, fungicides, herbicides/weedicides, and public health... products; and biological products comprise bio pesticides, bio fungicides, bio fertilizers, bio nematicides, and health and hygiene related products, as well as micro fertilizers and plant growth stimulants. The company also exports its products to Bangladesh and Afghanistan. In addition, it offers a range of diagnostic kits for various diseases ranging from infectious diseases to oncology. The company was founded in 1972 and is based in Bhopal, India. Read more
Incorporated
1972
Chairman
Dhirendra Dubey
Managing Director
Dhirendra Dubey
Headquarters
Bhopal, Madhya Pradesh
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of 3B BlackBio Dx Ltd is ₹1,189.00 (BSE) as of 27-Mar-2026 10:58 IST. 3B BlackBio Dx Ltd has given a return of 43.07% in the last 3 years.
The P/E ratio of 3B BlackBio Dx Ltd is 18.21 times as on 25-Mar-2026, a 31 discount to its peers’ median range of 26.24 times.
The P/B ratio of 3B BlackBio Dx Ltd is 3.26 times as on 25-Mar-2026, a 9 premium to its peers’ median range of 3.00 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
29.05
|
5.16
|
|
2024
|
20.54
|
2.96
|
|
2023
|
13.73
|
1.84
|
|
2022
|
7.94
|
1.67
|
|
2021
|
1.87
|
1.62
|
The 52-week high and low of 3B BlackBio Dx Ltd are Rs 2,019.90 and Rs 1,151.00 as of 27-Mar-2026.
3B BlackBio Dx Ltd has a market capitalisation of ₹ 1,046 Cr as on 25-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in 3B BlackBio Dx Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-29.70
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.